Den 29 aug tom 1 sep ska jag vara med i ett "Charity ride" för att samla in pengar åt EHC (den europeiska patientorganisationen för blödarsjuka). Jag och ett antal kollegor från Sobi ska cykla 460km från Bonn till Hamburg. Det är det fjärde året i rad som Sobi arrangerar en "Charity ride". Jag var med det första året (London-Paris) och nu är det dags igen!
Blödarsjuka är en mycket allvarlig livslång sjukdom men med kontinuerlig preventiv behandling kan de flesta patienter ändå leva ett normalt liv.
Together with a team of Sobi colleagues, I will be cycling about 460 km from Bonn to Hamburg from August 29 to September 1, 2019 in order to raise money for the European Haemophilia Consortium (EHC). The funds will be used to support projects for increased physical activity and an active life style for people with haemophilia.
This is the fourth stage of the Sobi Charity Bike Ride for Haemophilia that started in 2016 from London to Paris, continued in 2017 from Paris to Brussels, then in 2018 from Mainz to Brussels. I participated in the first ride in 2016 and it was a great experience. I am very excited about being able to participate once again, now from Bonn to Hamburg.
About the EHC
The European Haemophilia Consortium (EHC) is an international non-profit organisation that represents 46 national patients’ organisations of people with rare bleeding disorders from 27 Member States of the European Union (EU) and most Member States of the Council of Europe. The EHC represents approximately 90,000 people diagnosed with a rare bleeding condition such as haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders across Europe. However, it is estimated that many more live with an undiagnosed rare bleeding disorder.
Haemophilia is a type of bleeding disorder in which the blood does not clot properly. When a person with haemophilia bleeds it takes longer than normal for the bleeding to stop. This is because people with haemophilia don’t produce enough of an important protein that helps the blood to clot, called a ‘clotting factor’. Haemophilia is a rare disease that is usually inherited and is more common in males than females.
At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.